INTRODUCTION

Menopausal transition, or ‘perimenopause’, is a defined period beginning with the onset of irregular menstrual cycles until the last menstrual period and is marked by fluctuations in reproductive hormones. This period is characterized by irregularities of menses; lengthy and heavy menses with episodes of amenorrhea, sub-fertility, hot flushes which falls under vasomotor symptoms, a psychological symptom like insomnia. 4 years is an average span during which these symptoms appear prior menopause. Primary source of sex hormones like estrogen, progesterone and androgens in the ovary. Menopause resulting in infertility secondary to oocyte depletion is the major event. The woman holds her at high risk for endometrial hyperplasia and carcinoma when exposed to endogenous or exogenous estrogen in form of unopposed administration. According to a study, perimenopausal women showed greater symptoms as compared to menopausal women. The perimenopausal period has been considered a peak phase for the menopausal symptoms. Also, the period of post menopause showed declining symptoms in same women. An Indian study found that the perimenopausal
group included more prevalent vasomotor symptoms while postmenopausal age group were suffering from musculoskeletal symptoms in the majority. Greater prevalence of biological and psychological symptoms have been recorded in women with low socioeconomic status. 

Women all over the world now have to spend almost 1/3rd of their lives in menopause years because average life expectancy is increasing. The Collaborative Group on Hormonal Factors in Breast Cancer showed a significant increase in breast cancer risk in 52,000 women using HRT-Estrogen replacement therapy for >5 years.6-8 The WHI findings have drawn attention to non-hormonal treatments of hot flushes and other menopausal symptoms. Use of HRT, Bisphosphonates, SERMs and anabolic steroids are not devoid of adverse effect.9 It is need of the hour to carry researches for finding efficient, economic, natural and safer formulations to manage peri-menopausal symptoms. Present Pilot Study considers the four disorders a patient is suffering from, in perimenopause and aims to observe and record the serum estradiol fluctuations while receiving Ashwagandhadi Ksheer basti (administration of medicated regime per rectum) along with counselling in one group and counselling only in other group (Table 1-3).

**OBJECTIVES**

1. To evaluate the effect of Ashwagandhadi ksheerbasti on psychological symptoms and vasomotor symptoms during perimenopause.
2. To evaluate serum estradiol fluctuations in perimenopause with the administration of Ashwagandhadi kheer Basti.
3. To observe the efficacy of duration of basti administration.
4. To observe the effect of counselling in symptoms of perimenopause.

**MATERIAL AND METHODS**

**Table 1: Inclusion and Exclusion Criteria**

| Place of the Study       | MGACH & RC, Wardha |
|--------------------------|---------------------|
| Inclusion criteria       | Patient of age group - 41-50 years |
|                          | Patient suffering from peri menopausal psychological and vasomotor symptoms. (Meeting the criteria mentioned in standard score Scales) |
| Exclusion criteria       | Patient on hormone replacement therapy (H.R.T.) |
|                          | Patient with severe menorrhagia. |
|                          | Patients with any organic lesions of reproductive tract like tuberculosis, carcinoma and congenial deformities, or any other pelvic pathology. |
|                          | Patients with known case of adrenal hyperplasia, androgen secreting neoplasm, thyroid abnormalities, Cushing’s syndrome, cardiac diseases. |
|                          | Patient with hemoglobin < 7. |
|                          | Patients with known case of DM. |
|                          | Patients who are unwilling to become subject for study |
| Withdrawal Criteria      | In case of an acute or severe illness. |
|                          | In case, patient leaves against medical advice. |

**Table 2: Study Groups and Sample Size**

| 2-Groups                  | Group A- Intervention with Basti along with counselling Group B- Intervention with Counselling only |
|---------------------------|--------------------------------------------------------------------------------------------------|
| Total Sample size         | 20 female (10 in each group)                                                                      |
| Standard Pattern for basti instillation | Yogabasti - Alternate Ksheer (medicated milk) and medicated oil |
| Dose                      | Ksheer (Medicated milk)-364 ml, Medicated Oil- 64 ml                                              |
| Comparison                | Counselling / No other intervention                                                               |
| Ingredients of Ashwagandhadi oil (3 days Siddhi) | Ashwagandha |
|                          | Erandamool                                                                                       |
|                          | Rocksalt                                                                                        |
|                          | Sesame oil                                                                                       |
| Ingredients of Ashwagandhadi ksheer (Freshly prepared) | Ashwaganshada oil |
|                          | Rock salt                                                                                       |
|                          | Bruhat pachmool                                                                                  |
|                          | Laghu pachmool                                                                                   |
|                          | Makshika/Honey                                                                                   |
|                          | Godugdha/milk (fresh for each patient)                                                          |
Table 3: Screening and Investigations

| Screening Investigation | BSL | HB% |
|-------------------------|-----|-----|
| Parameters -1           |     |     |
| Hot flush               |     |     |
| Depression              |     |     |
| Panicking               |     |     |
| Parameter -2            |     |     |
| Serum estradiol level   |     |     |
| Timings of Basti in    | Post|     |
| Intervention            | menstrual 9th to 16th day |
| Intervention protocol- (Group A) | | |
| Counselling             |     |     |
| 3 days - Panchakol powder - 3 gm BID |
| 1 day - Whole body abhyanga and Svedan |
| 8 days - Basti          |     |     |
| Group B                 |     |     |
| Counselling             |     |     |

**Evaluation endpoints**

Following symptoms will be evaluated,

**Vasomotor symptom:** Hot flush

**Psychological symptoms:** Depression, Cognition, Insomnia

**Psychiatric disorders:** Schizophrenia, Bipolar disorders, Panic disorders,

**EXPECTED RESULTS**

Statistical analysis will be performed with Paired and unpaired t-test and the result will be drawn. HRT which is an estrogen replacement therapy in the deficient or lesser estrogen conditions like peri and post-menopause. We postulate a theory based on Ayurveda principle stating, the base of the reproductive system is in bone marrow/female reproductive component are generated and derived from the bone marrow (Majja-Shukra concept-Charak) The intervention category of drug (Tikta) and route of administration is an exclusive bone-bone -marrow treatment as per Ayurveda texts (Charak-Vagbhat) which can enhance the folliculogenesis and thereby estrogen secretions.

Recent studies showing bone marrow transplantation experiments in poor ovarian reserve to increase folliculogenesis and thereby ovarian hormone levels can be taken into consideration for supporting the postulated theory. (Mohasen Ghadi et al-2012)The estrogen is secreted from ovarian follicles which are said to be originated from bone marrow as per Ayurveda principle as well as recent animal studies. The more active and healthy bone marrow is, the more efficient is the folliculogenesis and estrogen secretion. Intervention possibly increases the rate of folliculogenesis or might increase the receptivity of follicles for FSH to enhance folliculogenesis and thereby more estrogen secretion.

To observe the estrogen fluctuations in serum by recording three samples at certain intervals of each patient, we tried to show the relationship of the drug, its route and serum estradiol levels, hypothesizing the intervention affects through bone marrow and folliculogenesis for enhancing or at least fluctuating serum estradiol levels.

**DISCUSSION**

Symptoms of perimenopause (Zeffcoat’s PG) in general and subjective parameters of present study fall in the criteria of Vata pitta disorders and hence abnormal perimenopause is an abnormal Vata-Pitta condition. The Basti (per rectal instillation of drugs) as the route itself is effective and indicated in Vata disorders and drug (Ashwagandhadi ksheer) itself is indicated in Pitta disorders. Vata resides in Asti (Bone)and its vitiation leads to athikshaya(degeneration of bones) and Basti is the key route of management for abnormal Asthi (Ayu). Bone marrow(Majja) is closely related to pitta and rakta and hence tikta drugs are advised as tikta normalizes pitta.

The principle treatment for bone-related disorders is Tikta-ksheer basti (Ashwagandhadi-Tikta). On 8th day Basti reaches to Asthi (Sushrut). Interrelationship of Asthi-majja -Shukra/Artava in female (Bone - Bone marrow and ovaries/follicles) Basti works in the bone, Bone marrow-majja- Neurological functions. Recent studies show bone marrow transplantation restores follicular maturation and steroid production in mouse models for primary ovarian failure. (Mohasen Ghadi et al.-2012)Follicular recruitment occurs in the bone marrow before ovaries. Shukra/Artava/ Female-reproductive
component-(HPO) is the product of Bone marrow (Ayu). Menopause-transition-hampering normal life-shukra/Artava malfunctioning.

**CONCLUSION**

It will be drawn after obtaining the results of the study.

**REFERENCES**

1. Soares CN, Taylor V. Effects and management of the menopausal transition in women with depression and bipolar disorder. J Clin Psychia 2007;68:16-21.
2. Baram DA, Stewart DE, Robinson GE. Physiology and symptoms of menopause. Menopause: A mental health practitioner’s guide. 2005:15-32.
3. Berg JA, Taylor DL. Symptom experience of Filipino American midlife women. Menopause 1999;6(2):105-14.
4. Goonaratna C, Fonseka P, Wijeywardene K. Perimenopausal symptoms in Sri Lankan women. Ceylon Med J 1999;44(2):63-9.
5. Lagos X, Navarro N, Illanes E, Bustos L. Prevalence of biological and psychological symptoms in perimenopausal women from different socioeconomic levels in the city of Temuco. Revista medica de Chile 1998;126(10):1189-94.
6. Nagar S, Dave P. Perception of women towards physiological problems faced at menopause. Anthropologist 2005;7(3):173-5.
7. Bluming AZ. Hormone replacement therapy: Benefits and risks for the general postmenopausal female population and for women with a history of previously treated breast cancer. In Seminars in Oncology 1993; 20(6):662-674.
8. Schiff I, Regestein Q, Tulchinsky D, Ryan KJ. Effects of estrogens on sleep and psychological state of hypogonadal women. JAMA 1979;242(22):2405-7.
9. Freedma RR, Woodwards S, Sabharwal SC. α2-Adrenergic mechanism in menopausal hot flushes. Obstetr Gynecol 1990;76(4):573-8.